BrainChild Bio, Inc.
BrainChild Bio develops CAR T-cell therapies for central nervous system tumors, prioritizing pediatric brain cancers such as diffuse intrinsic pontine glioma and extending its pipeline to adult tumors including glioblastoma and brain metastases. It aims to create safe and effective treatment options for children and adults with incurable brain tumors.
Facts
- Sectors
- Biotechnology Research
- Employees
- 11–50
- Stage
- Series A
- Founders
- Michael Jensen, MD
Is this your organization? Claim it
Financial Management Platforms with Kurt Shintaffer | CFO Weekly, Ep.144
In this episode of CFO Weekly, Kurt Shintaffer, Co-Founder and CFO of Apptio, joins Megan Weis to discuss the importance of connecting your technology investment decisions to drive better business outcomes, as well as how this enables users across disciplines to report, analyze, plan, and govern their investments collaboratively, efficiently, and with confidence. Read more about the episode here: https://insights.personiv.com/cfo-weekly/better-business-outcomes #cfoweekly #technologyinvestmentdecisions #financesoftware
People
-
Michael Jensen Founder, Chief Scientific Officer
-
Steven Brugger Executive, Chief Executive Officer